Please login to the form below

Not currently logged in
Email:
Password:

Dave Lemus joins Proteros as an executive board member

He joins the German biotech’s board from Medigene

Proteros, a private biotech based in Germany, has appointed Dave Lemus as an executive board member, chief operating officer and chief financial officer of Proteros Biostructures.

Additionally, he will serve in the role of non-executive board chairman of Proteros USA, the company’s newly-formed subsidiary in the US, where he will be based.

He said: “I am excited to assist the company in attaining its ambitious global goals and look forward to helping enable Proteros achieve its next stage of development.

“Proteros’ science base and numerous active collaborations with virtually all of the global pharmaceutical and biotech industry’s major players, provides a tremendous base from which to grow from.”

Prior to his new roles, Lemus was chief operating officer and chief financial officer of Medigene, assisting in its transformation into an immunotherapy-based company through the establishment of strategic partnerships.

He has also held roles with MorphoSys and Hoffman La Roche.

Torsten Neuefeind, chief executive officer of Proteros, said: “I am delighted to have Dave on board during what is a phase of rapid development and progress at Proteros.

“We have greatly appreciated his contributions over the last years in his service on our board, and I sincerely believe he can support us in achieving our goal to become a global leader on technically challenging and novel targets.”

9th January 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics